Not to worry mate. So if that is indeed what's playing out with the raise , then if we just run through some back of the envelope calc's here.If we firstly were to assume that ALL 240,000,000 million shares issued in February 2022 at 1.1 cents , and then added this 489,000,000 being raised at .0045 cents , then the ' Average ' price per share raised based on the say $2,400,000 raised at 1.1 and the $2,200,500 being raised at .0045 cents would be $4,600,500 / 729,000,000 = .0063107 average.So let's just call it 6.25 - 6.5 cents to get the assumed ' collective ' of Spoh's out at their break-even.But what's even more interesting from there if we simply look at the dilutionary effect across a sequence of re-rated market cap valuations based on the SOI now PLUS the suggested 489 million NEW shares.If we say look at a $30 million .....> $45 million .....> $60 million escalated milestone project valuations .So at $30 million with the current 2,733,551,728 total shares on issue we have a projected SP at $30 million of 1.1 cents , at $45 million 1.65 cents , and at $60 million would be 2.2 cents or a NEW all time high SP.So then when you add the 489 million you get a 15.2% dilution on the increase to total SOI of 3,222,551,728 and a NEW SP valuation trajectory of around .00925 cents at $30 million MC , 1.4 cents at $45 million , and .1.85 - 1.875 cents at the $60 million market cap valuation.So my point here is that while on paper , it would appear the .0045 cent suggested cap raise SP is a 25% discount to the last trade price of .006 cents , and even greater discount at .007 cents , the dilution to the SOI and potential subsequent project values at any given price point is more likely only 15%.And so that difference and the fact that the Soph's participation across 2 raises and 1 year is averaged at ABOVE the last trade price at point 625 - point 65 of a cent and NOT at the .006 level would seem to set up the raise more for success than disappointment I would think.I guess we'll see , but whenever you are getting the shares at a price ALREADY below the average over TWO significant raises including what Directors have contributed PLUS getting them at much less than what the Company even paid for these projects , you'd have to argue that you are doing extremely well to get set at these prices.So you could say that it is almost priced for ' perfection '......
- Forums
- ASX - By Stock
- CAV
- Ann: Trading Halt
CAV
carnavale resources limited
Add to My Watchlist
16.7%
!
0.4¢

Ann: Trading Halt, page-26
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $14.31M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $1.802K | 496.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
26 | 28968740 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 12078233 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
26 | 28968740 | 0.003 |
28 | 27802091 | 0.002 |
18 | 37792810 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 12078233 | 8 |
0.005 | 33997372 | 29 |
0.006 | 15806323 | 15 |
0.007 | 1185715 | 4 |
0.008 | 11296259 | 8 |
Last trade - 11.14am 04/07/2025 (20 minute delay) ? |
Featured News
CAV (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online